Clinical Trial Update: Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients [Phase 2]

View source ↗

Summary

A Pfizer-sponsored Phase 2 trial evaluated exemestane as neoadjuvant therapy in operable breast cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED